Search

MSK Kids researchers publish report of screening and testing for COVID-19 in pediatric cancer patients in New York City.

… Wednesday, May 13, 2020 Researchers from MSK Kids at Memorial Sloan Kettering Cancer Center (MSK) found that children with cancer are not at a higher risk of being affected by COVID-19. This new research led by Andrew Kung, MD, PhD, Chair of MSK Kids and his colleagues was published today in JAMA Oncology

An analysis of patients who received molecular testing at MSK has found that about half of those with hereditary gene mutations could benefit from treatment with therapies that target those alterations.

… Wednesday, June 16, 2021 The majority of cancers are caused by random genetic changes and environmental exposures — things like sunlight, tobacco smoke, and the human papillomavirus (HPV). But Memorial Sloan Kettering researchers have found that, at least among people with metastatic or recurrent disease

Doctors at Memorial Sloan Kettering Cancer Center (MSK) pioneered advances in many types of cancer treatment for patients in 2022. Here are some of the most important developments.

… Wednesday, December 14, 2022 Doctors at Memorial Sloan Kettering Cancer Center (MSK) pioneered advances in many types of cancer treatment for patients in 2022. Clinical trials reported results of cutting-edge treatments, including new types of immunotherapy , radiation therapy , and experimental targeted

Vice President Joseph Biden visited Memorial Sloan Kettering Cancer Center (MSK) for a roundtable discussion with MSK experts and members of the cancer community. The candid conversation, inspired by the “moonshot” initiative announced by President Obama, was led by Craig Thompson, MD, President and CEO of MSK. MSK’s Carol Brown, MD, Ross Levine, MD, and Robert Sidlow, MD, were also active participants in the discussion. For more information about the event or to request an interview with a MSK roundtable participant, please e-mail [email protected].

… Thursday, May 26, 2016 Vice President Joseph Biden visited Memorial Sloan Kettering Cancer Center (MSK) for a roundtable discussion with MSK experts and members of the cancer community. The candid conversation, inspired by the “moonshot” initiative announced by President Obama, was led by Craig Thompson

Earlier this year, MSK announced the formation of MSK Ventures, a dedicated venture capital fund which will enable MSK to systematically invest in and help develop, scale, and, in some instances, translate new discoveries and services while diversifying long-term revenue streams. Whitney Snider, MD, joined MSK as Inaugural Managing Partner, after most recently serving as Principle and Vice President of Life Sciences at Alexandria Venture Investments.

… Thursday, March 19, 2026 Earlier this year, MSK announced the formation of MSK Ventures , a dedicated venture capital fund which will enable MSK to systematically invest in and help develop, scale, and, in some instances, translate new discoveries and services while diversifying long-term revenue streams

Learn how advanced basal cell carcinoma can be treated with a new combination radiation and drug therapy.

… Thursday, April 18, 2024 Millions of Americans develop basal cell carcinoma basal cell carcinoma (BCC) on their skin, usually on their face, neck, or head. It’s the most common form of skin cancer skin cancer and is rarely fatal, but it can be uncomfortable and unsightly. BCC can usually be removed with

One of MSK’s leading immunologists turned 60 on Friday, and scientists came to celebrate.

… Monday, September 12, 2016 Alexander (Sasha) Rudensky with former students and colleagues Sasha Rudensky (center left) with former students and colleagues Greg Barton (left), Jason Fontenot (center right), and Nicholas Arpaia (right). Dr. Rudensky with Dr. Barton of the University of California, Berkeley

Physician-scientists at Memorial Sloan Kettering Cancer Center (MSK) recently published two papers that advance the science of addressing critical issues with CAR T cell therapy in patients with relapsed or refractory non-Hodgkin lymphomas, profound immune suppression, and predicting the likelihood of treatment failure.

… Tuesday, April 1, 2025 While chimeric antigen receptor (CAR) T cell therapy is an essential therapeutic option for prolonging survival in patients with relapsed or refractory non-Hodgkin lymphomas (NHL), profound immune suppression and predicting the likelihood of treatment failure remain significant

MSK nanotechnology researchers have developed an innovative approach for measuring the permeability of living tumors.

… Tuesday, February 23, 2016 Summary Tumor permeability can be a critical factor in how well a cancer therapy works. MSK researchers developed a method to measure this by creating living tumor spheroids and infiltrating them with very small carbon nanotubes that give off infrared light. The more light

Learn more about how MSK is helping a new generation of patients — including triathlete Derrick Edwin — to navigate work and careers while undergoing treatment for cancer.

… Thursday, April 10, 2025 One November morning in 2021, Derrick Edwin woke with pain in his side — as a triathlete in peak condition, he knew something was off. “Two months before, I had completed an Ironman — that’s a 2.4-mile swim, 112 miles on the bike, followed by a full marathon — and I felt great